Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Deborah Mulford, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

Office: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I was drawn to the field of oncology because it allows me to treat the whole person. The number of new and effective cancer therapies we can offer patients excites me, and it is incredibly rewarding to experience positive results with patients and families.

My practice style is patient- and family-focused. I work closely with a multidisciplinary team to determine the best, evidence-based treatment option for each individual. My primary focus is in the treatment of cancers originating from the lung and/or head and neck region. I am a native Rochesterian and am proud to have attended the University of Rochester for medical school.

Conditions I Treat:

- Head and neck cancers
- Lung cancer
- Other malignancies

Credentials

Specialties

  • Hematology
  • Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

1999
MD | University of Rochester

Post-doctoral Training & Residency

07/01/2002 - 06/30/2005
Fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center

07/01/2000 - 06/30/2002
Residency in Internal Medicine at New York University School of Medicine

07/01/1999 - 06/30/2000
Internship in Internal Medicine at New York University School of Medicine

VIEW ALL expand_more

Awards

2004 - 2006
NIH Clinical Loan Repayment Program
Sponsor: NIH

2003 - 2005
Lauri Strauss Leukemia Foundation Endowed Fellowship
Sponsor: Lauri Strauss Leukemia Foundation
Location: Memorial Sloan-Kettering Cancer Center, New York City, NY

2003 - 2005
Mortimer J. Lacher Fellowship Award
Location: Memorial Sloan-Kettering Cancer Center, New York City, NY

1996 - 1996
International Cancer Fellowship
Sponsor: University of Rochester Medical School
Location: Rochester, NY

1991
U.S. and European Patent-Photographic Apparatus for an Optical Instrument
Location: Polaroid Corporation, Boston, MA

1990
Warner King Prize
Location: Union College, Schenectady, NY

1989 - 1990
Stearns Prize
Location: Union College, Schenectady, NY

1988 - 1990
Eta Kappa Nu and Tau Beta Pi Engineering Honor Societies
Location: Union College, Schenectady, NY

1986 - 1990
Tidmarsh Scholarship for Piano
Location: Union College, Schenectady, NY

VIEW ALL expand_more

Clinical Trials

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis

Lead Researcher: Deborah Mulford MD

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression, is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving first-line pembrolizumab followed by pemetrexed and carboplatin with or without pembrolizumab works better in treating patients with non-squamous non-small cell cancer.

View Study Details

QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy

Lead Researcher: Deborah Mulford MD

This is a Phase IIb, single-arm, multicohort, open-label multicenter study of ALT-803 in combination with an FDA-approved PD-1/PD-L1 checkpoint inhibitor in patients with advanced cancers who have progressed following an initial response to treatment with PD-1/PD-L1 checkpoint inhibitor therapy. All patients will receive the combination treatment of PD-1/PD-L1 checkpoint inhibitor plus ALT-803 for up to 16 cycles. Each cycle is six weeks in duration. All patients will receive ALT-803 once every 3 weeks. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Radiologic evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months past administration of the first dose of study drug.

View Study Details

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer (MS200647-0037)

Lead Researcher: Deborah Mulford MD

The study will evaluate M7824 monotherapy versus pembrolizumab as first-line treatment for participants with advanced non-small-cell lung carcinoma (NSCLC) with high PD-L1-tumor expression (PD-L1 stand for Programmed Death-Ligand 1).

View Study Details

Publications

Journal Articles

10/2014
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. "SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia." British journal of haematology.. 2014 Oct 0; 167(2):233-7. Epub 2014 Jul 18.

12/2013
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. "A phase I study of decitabine and rapamycin in relapsed/refractory AML." Leukemia research.. 2013 Dec 0; 37(12):1622-7. Epub 2013 Sep 08.

4/30/2012
Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)." Journal of hematology & oncology. 2012 Apr 30; 5:18. Epub 2012 Apr 30.

Books & Chapters

2006
Chapter Title: Monoclonal Antibody Therapies of Cancer
Book Title: Cancer Chemotherapy and Biotherapy
Author List: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Published By: Baltimore: Lippincott, Williams, And Wilkins 2006

VIEW ALL PUBLICATIONS